Environmental risk assessment of human pharmaceuticals in the European Union: A case study with the β-blocker atenolol.
Küster A, Alder AC, Escher BI, Duis K, Fenner K, Garric J, Hutchinson TH, Lapen DR, Péry A, Römbke J, Snape J, Ternes T, Topp E, Wehrhan A, Knacker T.
Küster A, et al. Among authors: pery a.
Integr Environ Assess Manag. 2010 Jul;6 Suppl:514-23. doi: 10.1897/IEAM_2009-050.1.
Integr Environ Assess Manag. 2010.
PMID: 19886730